insights_auto
Why is CRSP up 5,85%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
53,39 USD
arrow_upward
+5,85%(+2,95) 1D
54,10 USD
arrow_upward
+1,33% (+0,71)bedtimeAfter hours
Closed: 9-окт., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
50,82 USD
High
54,07 USD
Low
50,52 USD
Mkt. cap
5,16 млд
Avg. vol.
1,62 млн
Volume
1,47 млн
52-wk high
78,00 USD
52-wk low
44,12 USD
EPS
-4,76 USD
Beta
1,45
Shares outstanding
96,69 млн
No. of employees
393
Open
50,82 USD
High
54,07 USD
Low
50,52 USD
Mkt. cap
5,16 млд
Avg. vol.
1,62 млн
Volume
1,47 млн
52-wk high
78,00 USD
52-wk low
44,12 USD
EPS
-4,76 USD
Beta
1,45
Shares outstanding
96,69 млн
No. of employees
393
News stories
From web sources and news partners
Simply Wall Street
·
22 саат мурун
Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock
MarketBeat
·
1 күн мурун
CRISPR Therapeutics (NASDAQ:CRSP) Shares Climb 5.7% - What's Next?
The Motley Fool
·
1 күн мурун
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Zacks
·
1 күн мурун
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG